The goal of this observational study is to learn about the molecular characteristics of colorectal polyps in patients with metabolic dysfunction-associated steatohepatitis (MASH) compared to individuals without fatty liver, and to identify potential transcriptomic biomarkers for high-risk polyps. The main questions it aims to answer are: What are the key gene expression differences in adenomatous polyps between MASH patients and non-fatty liver individuals? Can specific high-risk transcriptional molecules in plasma and polyp tissue serve as biomarkers for MASH-related colorectal polyps? Participants already scheduled for colonoscopic polypectomy as part of their routine care will provide a small portion of their polyp tissue, residual plasma from standard blood tests, and allow use of their stored pathological slides for research; they will also be followed up every six months.
Eligibility
Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
1. Diagnosis of MAFLD conforms to the "Guidelines for the Prevention and Treatment of Non-alcoholic Fatty Liver Disease" (2018 Edition);
2. Male or female patients aged 18-70 years;
3. Signed informed consent form and explanation of the specific study protocol.
Exclusion Criteria:
1. Chronic liver disease due to other etiologies (alcoholic, viral, autoimmune, drug-induced, etc.), decompensated cirrhosis, primary liver cancer;
2. Underlying diseases of other vital organs (heart, kidney, lung, etc.) and bleeding disorders;
3. Individuals lacking legal capacity or with poor insight.
Primary outcome measure(s)
Expression Levels of High-Risk Transcriptional Molecules in Colorectal Polyp Tissues — Day1 Single-cell RNA sequencing (scRNA-seq) technology will be used to perform transcriptomic analysis on colorectal polyp tissues from enrolled patients (6 cases) to screen for differentially expressed genes associated with MASH. Subsequently, real-time quantitative polymerase chain reaction (RT-qPCR) will be used to validate the expression levels of candidate genes in polyp tissues from all patients in the cohort.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.